ClinicalTrials.gg
Drug

Olverembatinib clinical trials

Also written HQP1351.

studies test it
28
open now
19
in phase 3
4
first study started
2018

How each study uses olverembatinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the olverembatinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Olverembatinib
16
Blinatumomab
2

Development codes

HQP1351
6

Studies by the year they started

27 studies that test it; most in 2022 (6); 1 more planned to start later

Studies that test olverembatinib, by start year
YearStudies
20181
20195
20226
20233
20246
20254
20262

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
8
Phase 2
16
Phase 3
4
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 9 · Other 19

Ascentage Pharma Group Inc. (9) · Institute of Hematology & Blood Diseases Hospital, China (7) · M.D. Anderson Cancer Center (3) · The First Affiliated Hospital of Soochow University (3) · First Affiliated Hospital of Zhejiang University (1) · Nanfang Hospital, Southern Medical University (1) · Xijing Hospital (1) · Chen Suning (1)

Often tested with

Tested in the same studies.

Lisaftoclax (1) · Dexamethasone (1) · Allogeneic Anti-CD19 T-cells ThisCART19A (1) · Chimeric Antigen Receptor T-cells (1) · Venetoclax (1) · Azacitidine (1) · Prednisone (1) · Blinatumomab (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 7, 1 in phase 3

Studies that test olverembatinib, phase 3 first.

Studies

Open first, then newest update. How each study uses olverembatinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 28

See all 28 studies that test olverembatinib →

Given beside what is tested · 4 — olverembatinib is usual care or a partner of the new treatment

Codes

What other systems call olverembatinib · ClinicalTrials.gg INT006263

  • MeSH (NLM) C579813olverembatinibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) KV1M7Q3CBPOLVEREMBATINIBConfirmed FDA, NLM, Wikidata
  • Wikidata Q123846205olverembatinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C165549OlverembatinibOne source FDA
  • DrugBank DB16185One source Wikidata

Also registered as olverembatinib dimesylate (UNII NPJ9AW8AZR).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.